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Abstract: Molecular oxygen is toxic for anaerobic organisms but it is also obvious that oxygen is poisonous to aerobic or-
ganisms as well, since oxygen plays an essential role for inducing molecular damage. Molecular oxygen is a triplet radical 
in its ground-stage (.O-O.) and has two unpaired electrons that can undergoes consecutive reductions of one electron and 
generates other more reactive forms of oxygen known as free radicals and reactive oxygen species. These reactants (includ-
ing superoxide radicals, hydroxyl radicals) possess variable degrees of toxicity.  
Nitric oxide (NO•) contains one unpaired electron and is, therefore, a radical. NO• is generated in biological tissues by 
specific nitric oxide synthases and acts as an important biological signal. Excessive nitric oxide production, under patho-
logical conditions, leads to detrimental effects of this molecule on tissues, which can be attributed to its diffusion-limited re-
action with superoxide to form the powerful and toxic oxidant, peroxynitrite. 
Reactive oxygen and nitrogen species are molecular “renegades”; these highly unstable products tend to react rapidly with 
adjacent molecules, donating, abstracting, or even sharing their outer orbital electron(s). This reaction not only changes 
the target molecule, but often passes the unpaired electron along to the target, generating a second free radical, which can 
then go on to react with a new target amplifying their effects. 
This review describes the mechanisms of oxidative damage and its relationship with the most highly studied neurodegen-
erative diseases and the roles of melatonin as free radical scavenger and neurocytoskeletal protector. 
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INTRODUCTION 
  Free radicals (pro-oxidants) are highly reactive, unstable 
molecules that have an unpaired electron in their outer shell. 
They react with several cellular components including nu-
cleic acids, proteins, fatty acids, complex lipids, carbohy-
drates, etc. [41]. Reactive oxygen (ROS) and nitrogen (RNS) 
species are formed during normal metabolic activity in a 
variety of biochemical reactions and cellular function. Their 
beneficial effects occur at low concentrations and involve 
physiological roles in cellular signaling systems, induction of 
a mitogenic response, and cellular responses against infec-
tious agents [125]. Under physiological conditions, the 
steady-state formation of ROS and RNS is normally bal-
anced by a similar rate of consumption by antioxidants. Oxi-
dative stress results from an imbalance between formation 
and neutralization of free radicals. Pathologic processes, 
such as inflammation, ischemia, cancer, neurodegenerative 
disorders, etc. disrupt this balance by increasing the forma-
tion of free radicals in proportion to the available antioxi-
dants. The reactions between cellular components and free 
radicals lead to immediate damage or death of cells in   
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various tissues, including the central nervous system (CNS) 
[4, 45]. 
  Examples of free radicals are hydrogen peroxide, hy-
droxyl radical, nitric oxide, superoxide anion and peroxyl 
radical. Superoxide is generated via several cellular oxidase 
systems. Once formed, it participates in several reactions 
yielding various reactive products such as hydrogen perox-
ide, peroxynitrite, etc. In turn, these can lead to chain reac-
tion byproducts that also act to damage cells (e.g., lipid per-
oxidation products). An example of a very potent reactant is 
peroxynitrite which is 1,000 times more potent as an oxidiz-
ing compound than hydrogen peroxide [124, 25].
  The whole nervous system is rich in metals, particularly, 
the brain is a specialized organ that accumulates iron ions 
and it is specially susceptible to oxidative damage since has 
a high metabolic activity and high content of unsaturated 
fatty acid [22, 45]. The high level of brain iron may be es-
sential, particularly during development, but its presence also 
means that injury to brain cells may release iron ions that can 
lead to oxidative stress via the iron-catalyzed formation of 
reactive oxygen species [53, 65]. 
  Neurodegenerative diseases are a heterogeneous group of 
disorders characterized by the gradually progressive and 
irreversible destruction of specific neuronal populations. 
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systems is complex and multifactorial. Although the etiology 
of the major neurodegenerative (including Parkinson's dis-
ease, Alzheimer's disease, Huntington’s disease and amyo-
trophic lateral sclerosis) is unknown, there is substantial evi-
dence that oxidative stress is a common critical factor in 
these diseases [63, 77]. 
  Antioxidant properties of melatonin and its metabolites 
[47, 68, 69, 123] are connected with its neuroprotective ac-
tivity in several degenerative disorders. The efficacy of 
melatonin in the inhibition of the oxidative stress has been 
estimated in various neurodegenerative disorders such as 
Alzheimer's or Parkinson's disease [3, 62, 104, 111]. Mela-
tonin has a clinical potential for the treatment of neurode-
generative disorders in the central as well as peripheral nerv-
ous system [92-103]. 
LIFE, BEFORE AND AFTER OXYGEN 
  The relationship between changes in atmospheric oxygen 
levels and the evolution of life on the earth are well docu-
mented biologically [2, 60]. There was a delayed of more 
than a billion years between the origin of cyanobacteria and 
the moment at which the levels of oxygen began to accumu-
late in the atmosphere [8, 16, 120]. This delay was due to the 
high presence of dissolved ferrous ion in the oceans, which 
reacted with free oxygen forming large ferrous oxide depos-
its. Until then, the only existing organisms were anaerobic 
cells. The gradual accumulation of oxygen during evolution 
of organisms that underwent photosynthesis provided the 
necessary elements for subsequent evolution of aerobic or-
ganisms (1,500 million years ago) and must have represented 
a cataclysm in the history of life [56]. Using oxygen for the 
generation of energy, aerobic cells obtained more energy 
from reduced substrates like glucose, due to the complete 
oxidation of the substrate to CO2. These reactions are sum-
marized as follows [2]. 
(Anaerobic metabolism) glucose  2 lactate + 56 Kcal/mol 
glucose 
(Aerobic metabolism) glucose + 6O2  6CO2 + 6H2O + 686 
Kcal/mol glucose 
  Because of this, aerobic life forms had an advantage over 
anaerobes. Anaerobic organisms were also at a disadvantage 
because the extra oxygen was toxic to them. Oxygen me-
tabolites are toxic to all life forms. For instance, obligated 
anaerobic organisms develop only in the absence of oxygen. 
Oxygen toxicity raises several questions: why it is toxic? 
Why can aerobic organisms prosper in an oxygen-containing 
atmosphere? Oxygen, in its fundamental state is not toxic, 
nevertheless, due to its electronic structure, which is includes 
two unpaired electrons. There are restrictions on its reactivity 
as an electron acceptor. It has been proposed that reaction of 
O2 + 4e + 4H
+  2H2O includes 4 univalent steps (only one 
electron is transferred):  
O2 + 1e  O2
•
O2
•+ 1e + 2H
+ H2O2
H2O2 + 1e + H
+ H3O2  H2O + HO
•
HO
• + 1e + H
+ H2O
Net: O2 + 4e + 4H
+  2H2O
  If oxygen reacts in this manner (and probably it does), 
the production of superoxide anion (O2
•) and hydroxyl radi-
cal (HO
•) are intermediates; this represents a major problem 
for organisms, since these intermediates are potent oxidizing 
agents. HO
• is the strongest oxidizing agent known; this 
radical can be formed in the following reaction: 
H2O2 + O2
•  O2 + OH
 + HO
•
  Each oxygen species represents a potential threat for cells 
due to the damage that each can cause to all biomolecules, 
especially proteins and lipids. In other words, oxygen toxic-
ity is due to the inherent toxicity of the reactive species, ei-
ther free radicals or other metabolites formed from it [57]. 
ENZYME SYSTEMS AND FREE RADICAL INJURY 
  Accumulative brain injury induced by free radicals is a 
factor in aging and neurodegenerative diseases [17, 46, 48, 
49]. Superoxide anion, O2
• is enzymatically produced by the 
action of cytochrome oxidase, NADH oxido-reductase, xan-
thine oxidase and phagocytic oxidases. In the latter case O2
•
is use to eliminate bacteria or tumor cells[29, 66] while O2
•
is toxic by itself, it can be converted to reactants that are 
even more reactive. 
  Hydrogen peroxide (H2O2) is formed within the cells by 
the interaction of two O2
• in the presence of superoxide 
dismutase (SOD). Isoforms of SOD in mitochondria and 
cytosol have been described. Also, H2O2 is formed by two 
electron reduction of O2.
  For the next step either a ferrous or cuprous ion are re-
quired in order to produce the anion OH
, which is non-
toxic, plus the radical HO
•, which is highly toxic. Cationic 
iron is the transition metal most often available in this reac-
tion. The HO
• reacts easily and indiscriminately with any 
molecule near to it, and causes damage and production of 
secondary free radicals. It reacts at a diffusion-controlled 
rate, either by adding or absorbing a hydrogen atom from 
other molecules [128]. 
  Free radical damage to macromolecules such as DNA, 
proteins, and polyunsaturated fatty acids (PUFA) probably 
produces the most notable functional cellular deficits [48, 
122]. PUFA are particularly susceptible to free radicals and 
once the damage has begun, the reaction is self propagating. 
In theory, all the lipids in the organism could be oxidized. 
Initially, free radicals attack methylenic groups adjacent or 
between ethylenic bonds. Secondly, a chain reaction takes 
place leading to lipid radicals, alkoxylic and peroxyl radi-
cals. The final products are non-radicals such as alkenes and 
carbonyl components. Some of these final products are de-
tectable and useful in order to measure the level of lipid per-
oxidation in a procedure that involves its reactivity with 
thiobarbituric acid. The peroxyl radical (ROO
•) formed dur-
ing the propagation phase is toxic enough to restart the per-
oxidation of another PUFA[93]. 
  Products of lipid peroxidation can achieve access to the 
nucleus and harm DNA, besides changing the physiology 
and structure of the cellular membrane. These changes may 
be involved in cancer initiation among other pathological 
processes [21]. Also, cytoskeletal organization is damaged 
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role in neuronal physiology and is damaged in neurodegen-
erative diseases. Free radicals cause a cytoskeletal to col-
lapse around the nucleus. H2O2 produces neurocytoskeletal 
damage similar to that found in neurodegenerative diseases. 
Moreover, free radicals produce neurite damage, and neu-
ronal loss [48, 87] and microtubule network is disrupted in 
cortical neurons exposed to high levels of free radicals [48]. 
Additionally, cortical neurons incubated with H2O2 show 
distribution changes in beta-tubulin and the 2 isoforms of 
microtubule associated protein (MAP2) and an abnormal 
microtubule organization [122]. Moreover, cytoskeletal-
dependent functions are affected by free radicals. This notion 
is supported by the fact that H2O2 inhibits cytoskeletal de-
pendent processes such as dopamine release by the substan-
tia nigra pars compacta of guinea pig brain [93].  
NITRIC OXIDE: SYNTHESIS AND MECHANISMS 
OF ACTION 
  Nitric oxide is a multifunctional molecule that partici-
pates in processes such as vasodilatation, bronchodilatation, 
neurotransmission, antimicrobial activity, inhibition of both 
phagocyte and platelet aggregation [32, 34, 36,40], regula-
tion of cytochrome c oxidase in the mitochondrial respiratory 
chain [18-20, 30, 32, 112] and mitochondrial biogenesis 
[79]. As a chemical signal, NO participates through binding 
and activation of guanylate cyclase and causes smooth mus-
cle relaxation, and a role of NO signaling in response to N-
methyl-D-aspartate (NMDA) activated receptors has been 
described [5]. On the other hand, the mechanism by which 
tumor cells are eliminated in rodent’s activated macrophages 
depends on L-arginine [51]; it is hypothesized that macro-
phages synthesized NO [52] which may be cytostatic and 
cytolytic if it is produced in higher quantities. Reactive ni-
trogen species derived from NO such as nitroxyl and per-
oxynitrite are essential in this process [119]. 
  NO is produced from the enzymatic conversion of the L-
arginine mediated by oxide nitric synthase (NOS). The proc-
ess consumes five electrons and results in formation of L-
citrulline and NO, with the participation of electron enzy-
matic transporters. Such synthesis involves the successive 
oxidation with the use of NADPH as a transporter of elec-
trons donated by O2. NOS contains a reductase and oxy-
genase domain, with specific recognition sites for flavine 
mononucleotide(FMN), flavine-adenine dinucleotide (FAD), 
and nicotinamide-adenine phosphate dinucleotide (NADPH). 
NADPH, FMN, and FAD transport electrons to heme mole-
cules bound to the oxygenase domain of the enzyme [29, 
122]. The electrons flow from one transporter molecule to 
another, from the reductase domain of the NOS to the heme 
group, and from the heme to the activated O2 (O-O) in order 
to modify the substrate (L-arginine) that will finally result in 
L-citrulline and NO production [18]. 
  NOS was originally purified from rat cerebellum [14] 
and several isoforms were described, although expression of 
these enzymes is not tissue specific [36, 43, 118]. The endo-
thelial NOS (eNOS, NOS type ) is located in the vascular 
endothelium and related mainly with the mechanism of 
smooth muscle relaxation. Neuronal NOS (nNOS, NOS type 
) is related with signal transduction in peripheral and central 
neurons. Both isoforms are calcium-calmodulin dependent. 
Inducible NOS (iNOS, NOS type ) was isolated originally 
from murine macrophages; it binds calmodulin but its activ-
ity is independent of intracellular calcium. Its expression 
occurs in response to inflammatory cytokines such as inter-
leukin 1 (IL-1) interleukin 2 (IL-2), tumor necrosis factor 
alpha (TNF-) or by lipopolysaccharide S (LPS). Interferon 
gamma (IFN-) acts in a synergistic formin most cases [74]. 
  The difference relative to calmodulin dependence be-
tween iNOS and eNOS is that iNOS has strongly coupled 
domains for the calmodulin structure even with the lack of 
calcium. eNOS and nNOS require previous formation of 
calcium-calmodulin complex, followed by the enzymatic 
engagement, for which prior rises of intracellular calcium are 
required [36].  
  The NOS in absence of L-arginine works in an uncoupled 
mode and produces large quantities of O2
•. NO can react 
with molecular O2 giving highly reactive radicals in addition 
to nitrites and nitrates, which are easily measurable. Under 
physiological conditions, O2 is not the primary target of NO. 
The most probable reactions are: 
2NO
• + O2  2NO2
• NO2O4
NO2O4 + H2O  HNO2 (nitrite) + HNO3 (nitrate) 
NO
• + H2O  NO2O3
NO2O3 + H2O  HNO2
  NO also reacts with O2
• initiately, yielding NOO
- and 
eventually HO
•, both of which are highly reactive; moreover, 
intermediate products are powerful inducers of lipid, protein, 
and DNA peroxidation; the consequences of these reactions 
are analyzed later[136]. 
NO
• + O2
•  OONO
•  OONOH  NO2 + HO
•
  With transition metals, especially heme iron, NO binds to 
the heme moiety of guanylyl cyclase and activates it to form 
cGMP. When cyclic oxygenase binds to the heme group the 
production of prostaglandin is increased; as a result, other 
enzymes that contain iron within a heme group are targets of 
NO. Catalase, cytochrome C, hemoglobin and peroxidase are 
examples: 
NO
• + X-Fe
x  (X- Fe
x - NO
•)  X-Fe
x-1- NO
+ (nitrosum 
ion) 
NO
• + Y-Fe
y  (Y- Fe
y - NO
•)  Y-Fe
y-1- NO
- (nitroxidum 
ion) 
NO
• + Hb(Fe
2+)O2  Hb (Fe
3+) + NO3
-
  DNA damage induced by NO or ONOO
- activates poly-
ADP ribose synthetase (PARS) which coordinates DNA re-
pair through the addition of ADP-ribose and the regulation of 
histones, high mobility proteins (HMGPs), nuclear matrix 
proteins (NMPs), topoisomerase  and the Ca
++-Mg
++-depen-
dent endonuclease. When NO inhibits ribonucleotide reduc-
tase (RR) the delivery of deoxyribonucleotide triphosphate is 
decreased (NTPdNTP). The prolonged repair of DNA 
increases the activation of PARS. At the same time, constitu-
tive poly-ADP ribose glycohydrolase degrades poly-ADP 
ribose. Four ATP molecules are required to rebuild nico-
tineadenine-diphosphate (NADP) from nicotinamide. Glyco-206    Current Neuropharmacology, 2008, Vol. 6, No. 3 Ortiz et al. 
hydrolase from poly-ADP-ribose and PARS initiates a vi-
cious cycle which reduces the levels of NAD, cellular energy 
and, ultimately, produces cell death [43, 137]. Because of 
these findings, NO is often considered as a dangerous mole-
cule more than an essential element in neurophysiology 
[7,76]. 
  Because NO has an important role in neurotransmission 
it is important to consider the mechanisms involved in its 
synthesis. NO production requires the engagement of cal-
cium-calmodulin complex for the activation of constitutive 
synthases in neurons and endothelial cells (nNOS and eNOS) 
[36]. This is a very refined mechanism, with the amounts of 
NO being limited and precise. The production of NO in in-
tact neurons occurs in response to excitatory stimuli that re-
quired Ca
++ [38]. According to the location of the enzyme, 
activation of NOS is coupled to: a), stimulation of postsyn-
aptic receptors by neurotransmitters leading to the mobiliza-
tion of calcium, and, b), action potentials in the presynaptic 
terminals that induce calcium flows through voltage sensible 
channels [105, 136]. 
  The activation of glutamate receptors is the main post-
synaptic stimulus for NO synthesis. NMDA receptors asso-
ciated with ionic channels have a high permeability to cal-
cium [39]; although other ionic channels associated with 
glutamate receptors like alpha amino-3-hydroxy-5-methyl-4 
isoxazolpropionate (AMPA) and kainate sensitive receptors
[81], have also been implicated [126]. Other neuromodula-
tors or neurotransmitters possibly related with NO synthesis 
are serotonin, bradykinin, acetylcholine, and noradrenaline
[91]. Even though neuronal and endothelial synthases are 
considered constitutive, these molecules can also be induced 
by particular events such as neuronal plasticity, develop-
ment, stress and direct lesions. Rather few neurons have been 
detected that expressed messenger RNA (mRNA) for NOS 
in lumbar ganglia of normal rats. Nevertheless, increased 
levels of NOS mRNA were found in one third of the neurons 
two days after the transection of the sciatic nerve, and this 
rise was maintained for at least two months [129]. 
  An increase in the levels of NOS mRNA has also been 
detected in response to stress [24], lactation [27], in the pitui-
tary gland in response to gonadectomy and in the hippocam-
pus as result of Alzheimer’s therapy with Tacrine and lith-
ium[6]. 
  In the pineal gland the production of NOS is regulated by 
a physiological stimulus. After 8 days of constant light expo-
sure (which reduces melatonin synthesis), the activity of 
NOS decreases by 80% and the normal activity is restored by 
normal light/dark cycles for two days. Noradrenaline appears 
responsible for this photoneural regulation[106]. 
  A problem with NO occurs when it is produced in large 
quantities. iNOS can produce high amounts of NO for long 
periods. The iNOS route therefore represents a response 
element of the cytotoxic cellular immune response, and the 
induction of iNOS results in 30-fold increase in NO forma-
tion in the CNS [122]. 
  Macrophages, smooth muscle cells, and endothelial cells 
express iNOS when induced by proinflammatory agents such 
as LPS, IL-1 and/or TNF-. Structurally, iNOS is strongly 
bounded to calmodulin; therefore, calcium-calmodulin com-
plex is not required for activation. The main step in the syn-
thesis of NO is the cellular concentration of the enzyme; its 
signaling pathway involves protein-kinase C [114] and in-
duces the activation of the iNOS gene. ADP-ribosylation
represents a crucial point in this signaling pathway [50]. It 
has been observed that the ADP-ribosylation inhibitors such 
as nicotinamide and benzimidine prevent the induction of 
NOS activity by IFN- and LPS in macrophages. Once iNOS 
has been activated, the synthesis of NO from L-arginine can 
reach a rate of 100nmol/h per mg of macrophage activated 
protein; this rate can be maintained for a long period of time. 
The regulation is at the transcriptional level [18, 108]. 
  The properties of NO are peculiar. For example, though it 
is a gas (in paranasal sinus and lungs, it is maintained as 
such) it stays dissolved in solution as a non-electrolytic sub-
stance capable of spreading to any compartment, since it is 
both liposoluble and hydrosoluble. NO at 1 nM is sufficient 
to interact with a billion synapses [81]. The half life of the 
NO is very short (5 seconds), but its diffusion is extremely 
rapid. Yet at 20 m beyond its production site, the concen-
tration is reduced to 10%. In spite of such a short life, NO 
generated at a given point can influence a radius of approxi-
mately 0.3 mm (the extent of the synaptic groove is about of 
20 nm). Moreover, NO affects neuronal structure. It induces 
neurite formation and dendrite branching in neuronal cells 
[134]. During development it also orchestrates neurite out-
growth and filopodial dynamics, cell migration of enteric 
neurons, glial migration and axonogenesis of pioneer fibers 
and it may regulate cell motility in the developing and re-
generating vertebrate nervous system [13]. In addition, evi-
dence has suggested that dementias are cytoskeletal disorders 
that involve loss of axons and dendrites of neurons in the 
CNS and consequently disruption of synaptic connectivity 
[11].  
With respect to mitochondrial cytochrome c oxidase 
regulation, NO binds reversibly to the binuclear oxygen 
binding site in cytochrome c oxidase (complex IV) in com-
petition with oxygen [19, 31, 75], this results in rapid inhibi-
tion of respiration in whole mitochondria and in the presence 
of physiological levels of O2. The mechanisms involved are 
complex, with greater inhibition occurring as the O2 concen-
tration decreases, through a mechanism that includes regula-
tion by the mitochondrial inner membrane [20, 30, 112]. 
Interestingly, mitochondria has one NOS isoform (nNOS 
modified posttranslational), it is consistent with direct regu-
lation of mitochondrial energy production by NO [33]. 
Higher NO levels disrupt the respiratory chain and may 
cause changes in mitochondrial calcium flux [133]. It was 
suggested that NO is probably the primary agent involved in 
preferential complex I inhibition following acute glutathione 
depletion in dopaminergic neurons in PD [54,107]. In con-
trast, other RNS, such as N2O3 and ONOO
- alter mitochon-
drial function through the irreversible modification of pro-
teins. For instance, ONOO
- induces inhibition of complex II, 
inhibition of the ATP synthase and nitration of Mn superox-
idedismutase[26,67,89]. In addition, radical nitroxyl (HNO) 
inhibits mitochondrial respiration through the inhibition of 
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hydrogenase), most probably via modification of specific 
cysteine residues in the proteins [113]. 
FREE RADICALS AND NEURODEGENERATIVE 
DISEASES 
  Recent evidence has focused attention on the role of oxi-
dative stress in various acute and chronic neurodegenerative 
diseases [87]. An increasing number of physicians are also 
recommending antioxidant therapies, such as high doses of 
vitamin E, for subjects with AD and other neurodegenerative 
disorders. Vitamin E, Ginkgo biloba, and selegiline are three 
putative antioxidants that have been tested in randomized 
multicenter trials in the US [35]. 
  Oxidative insults, whether over-excitation, excessive 
release of glutamate or ATP depletion caused by stroke, 
ischemia or inflammation, exposure to ionizing radiation, 
heavy-metal ions or oxidized lipoproteins may initiate vari-
ous signaling cascades leading to apoptotic cell death and 
neurodegenerative disorders [121]. Pathophysiologic proc-
esses common to both vascular (multi-infarct) dementia and 
dementia of the Alzheimer’s type may include microglial 
activation with the resultant generation of inflammatory cy-
tokines and neurotoxic free radicals, decreased secretion of 
nerve growth factor by astrocytes, excess release of gluta-
mate with associated neurotoxicity, and loss of cholinergic 
neurons [73]. 
  Mitochondria are intimately involved in the production of 
ROS through one-electron carriers in the respiratory chain 
(see Fig. 1); mitochondrial structures are also very suscepti-
ble to oxidative stress, as evidenced by massive induction of 
lipid peroxidation, protein oxidation, and mitochondrial 
DNA (mtDNA) mutations [64]. Oxidative stress can induce 
apoptotic death and mitochondria have a central role in this 
and other types of apoptosis, since cytochrome c release in 
the cytoplasm and opening of the permeability transition 
pore are important events into the apoptotic cascade. Muta-
tions in mtDNA have profound implications. Maternal in-
heritance of mtDNA is basic for hereditary mitochondrial 
cytopathies;theaccumulationofsomaticmutationsof mtDNA 
with age the basis of mitochondrial theory of aging, which 
includes a vicious cycle of mtDNA damage, altered oxida-
tive phosphorylation and overproduction of ROS [61].
  The efficiency of the mitochondrial electron transport 
chain (ETC) is reduced in multiple tissues, including brain, 
from patients with Parkinson's disease (PD) and Alzheimer's 
disease (AD). The ETC defects are specific to each illness, 
e.g., complex  in PD and complex IV in AD. In mtDNA-
deficient clonal neuronal cells hybridized with mtDNA (“cy-
brids”) from PD or AD patientsthese defects are transferable 
with mtDNA and lead to increased production of ROS [117]. 
ETC inhibition in vivo increases production of the toxic OH
•,
but the underlying mechanisms vary as a function of which 
ETC complex is inhibited.  
  There exists the possibility that tryptamine-4,5-dione (T-
4,5-D) and perhaps other putative intraneuronal metabolites 
formed by the O2
--/H2O2/oxo-iron-mediated oxidations of 5-
hydroxytryptamine (5-HT, serotonin) might be endotoxins 
that contribute to neurodegeneration in brain regions inner-
vated by serotonergic neurons. These metabolites are caused 
by methamphetamine (MA), glutamate-mediated oxidative 
toxicity, ischemia-reperfusion, and other neurodegenerative 
brain disorders[131].  
  Also, metals have an important role in neurodegenera-
tion. Iron can contribute to free radical damage by catalyzing 
the formation of the OH
•, inducing secondary initiation of 
lipid peroxidation and by promoting the oxidation of pro-
teins. The iron chelator, deferoxamine, can limit these oxida-
tive reactions and it scavenges peroxynitrite independent of 
iron chelation[86]. The increase in brain iron associated with 
several neurodegenerative diseases may lead to an increased 
production of free radicals via the Fenton reaction. The in-
tracellular iron is usually tightly regulated, being bound by 
ferritin in an insoluble ferrihydrite core. The neurotoxin 6- 
hydroxydopamine (6-OHDA) releases iron from the ferritin 
core by reducing it to the ferrous form [32]. In the presence 
of ferritin, both 6-OHDA and THB strongly stimulate lipid 
peroxidation, an effect abolished by the addition of the iron 
chelator deferoxamine. These results suggest that ferritin 
iron release contributes to free radical-induced cell damage 
in vivo.
  Iron accumulation could be an important contributor to 
oxidative damage of AD [32]. Redox-active iron is associ-
ated with the senile plaques and neurofibrillary tangles, the 
pathological hallmark lesions of this disease. Iron associated 
with the lesion induces in situ oxidation and readily catalyzes 
an H2O2-dependent oxidation. With deferoxamine the iron 
can be re-bound to the lesions. Characterization of the iron-
binding site suggests that binding is dependent on available 
histidine residues and on protein conformation. 
  In relation to free radical membrane damage and neuro-
toxicity in AD, an emerging hypothesis contends that -
amyloid toxicity results from peptide-mediated free radical 
reactions and the generation of ROS. Recently, it has been 
reported that reactivity of -amyloid toward the oxidation-
sensitive enzyme glutamine synthetase is related to the pep-
tide's reactivity toward the spin trap phenyl-tert-butyl nitrone 
(PBN) and the neuronal damage may be due, in part, to oxi-
dative processes initiated by amyloid-derived free radicals 
species. Electron paramagnetic resonance (EPR) spin label-
ing techniques and spectrophotometric assays provide evi-
dence that a portion of synthetic -amyloid [26-36] demon-
strates hydrogen peroxide-like reactivity toward Fe
2+, nitrox-
ide spin probes, and membrane proteins of neocortical syn-
aptosomes [23]. 
Fig. (1). Oxygen and the continuity of life through the most suitable 
energy production (right). On the left side: metabolism, ageing and 
pathological conditions involving free radicals and oxidative stress. 208    Current Neuropharmacology, 2008, Vol. 6, No. 3 Ortiz et al. 
  Aluminum may facilitate increases in intracellular Ca
2+
and ROS, and potentially contributes to neurotoxicity in-
duced by other neurotoxins [127]. Although its mechanism 
of action is unknown, aluminum alters Ca
2+ flux and homeo-
stasis, and facilitates peroxidation of membrane lipids. Since 
both abnormal increases of intracellular Ca
2+ and oxygen 
free radicals are present in pathways leading to neurodegen-
eration, the effect of aluminum on these parameters was ex-
amined in vitro using primary cultures of cerebellar granule 
cells. Exposure to glutamate (1-300 M) caused a concentra-
tion-dependent uptake of 
45Ca in granule cells to a maximum 
of 280% of basal value. Pretreatment with AlCl3 (1-1000 
M) has no effect on 
45Ca accumulation, but increased the 
uptake induced by glutamate. Similarly, AlCl3 has no effect 
on intracellular free Ca
2+ levels measured using the fluores-
cent probe fura-2, but it potentated the increase induced by 
glutamate. The production of ROS was examined using the 
fluorescent probe dichlorofluorescin. By itself, AlCl3 had 
little effect on ROS production; however, AlCl3 pretreatment 
increased ROS production induced by 50 M Fe
2+ [78]. Such 
mechanisms may be involved in the progression of neurode-
generative diseases, including AD and amyotrophic lateral 
sclerosis (ALS). 
  AD and Familial ALS may be linked through a common 
mechanism. In Familial ALS, SOD-Cu(I) complexes are 
affected by H2O2 resulting in free radical production; in AD, 
the reduction of Cu(II) to Cu(I) by APP involves an electron-
transfer reaction and could lead to a production of OH
•, thus, 
copper-mediated toxicity of APP-Cu()/() complexes may 
contribute to neurodegeneration in AD[78]. 
  NO is involved in acquired immune deficiency syndrome 
(AIDS) dementia complex and viral encephalitis [58]. It has 
also been demonstrated increases in iNOS expression in 
brains of patients with multiple sclerosis [126], in AD [23], 
AIDS [72]. In AIDS mediated neurodegeneration, HIV, or 
the glycoprotein 120 (gp120) induces iNOS and, at the same 
time, releases macrophage proinflammatory cytokines. Cy-
tokines from macrophages or neurons induce iNOS in glial 
cells. Furthermore, gp120 protein is lethal for cortical neu-
rons in culture; this effect is reduced by NOS inhibitors [59].
Other proteins from VIH virus shield such as gp160, and 
gp41 induce iNOS in astrocytes and microglial cells cultures. 
The process is similar to the NMDA agonist receptor mecha-
nism, probably more related with peroxynitrite than NO [58]. 
Excessive activity of glutamate acting through NMDA re-
ceptors mediates cellular death in cerebral focal ischemia 
[116]. Neurotoxicity of glutamate plays an important role in 
neurodegenerative diseases such as Huntington and AD. Ac-
tivation of NMDA receptors for 5 minutes and the subse-
quent increase in intracellular calcium initiates the damage; 
if NMDA it is applied during 5 minutes to cortical neuron 
cells in culture it causes cellular death 24 hours later. This 
"delayed neurotoxicity” depends not only of ionic calcium 
influx but also on the influx mechanism, due to calcium ef-
flux through NMDA channels; this is the most toxic method 
in which to provoke damage. There are some possible 
mechanisms to protect against delayed neurotoxicity: a) in-
hibiting NOS; b) removing NO substrates (L-arginine) and c) 
in the presence of reduced hemoglobin, which is NO scaven-
ger. In knockout mice for nNOS, it is possible to avoid glu-
tamate neurotoxicity, as well as in oxygen-glucose combined 
deprivation [70].  
MELATONIN IN FREE RADICAL SCAVENGING 
PROCESSES 
  Evidence exists, as seen previously, for oxidative damage 
to macromolecules in ALS, Huntington disease, PD, and 
AD. Potential therapeutic agents, based on the pathophysiol-
ogy described, include inhibitors of glutamate release, an-
tagonists of excitatory aminoacids, strategies to improve 
mitochondrial function, trophic factors and free radical scav-
engers [35, 92]. 
 Melatonin  (N-acetyl-5-methoxytryptamine)  a  molecule 
produced by a diversity of organisms, from algae to humans, 
has an evolution parallel to that of aerobic metabolism [98, 
100, 135]. In all organisms melatonin is primarily produced 
during the night; this includes man. Melatonin is synthesized 
by the pineal gland, retina, gastrointestinal tract, etc, and is 
secreted by the pineal gland. Nevertheless, nocturnal mela-
tonin production decreases with age, such that in old animals 
the quantity of melatonin is very limited [92]. Melatonin 
protects against LPS-mediated toxicity in liver and brain 
[110, 121]. In animals treated by pentobarbital, there is a 
decrease in the levels of gluthatione peroxidase activity. 
Also, melatonin protects against the rise lipoperoxidation 
products induced by LPS [109, 110]. LPS is used to induce 
endotoxic shock in experimental animals [29, 66, 119, 130], 
and it stimulates the production of NO and free radicals, 
which promotes nuclear and mitochondrial DNA damage
[119]. There is evidence showing a quick diffusion of mela-
tonin into the nucleus; this protects DNA from genetic dam-
age induced by LPS [109, 110].  
  Melatonin’s capacity to reduce lipoperoxidation damage 
of the membrane lipids it is also manifested during the proc-
ess of ischemia-reperfusion. In a study of these phenomena, 
high quantities of highly toxic free radicals are generated, 
including O2
• and OH
•. The primary sources of these oxi-
dants include endothelial cells, macrophages, polymorpho-
nuclear leucocytes, and hepatic cells. Experimentally, ad-
vanced administration of melatonin in animals experiencing 
ischemia-reperfusion reduces the levels of malondialdehydes 
(MDA) and 4-hydroxyalkenals (4-HDA), metabolites of 
membrane-lipid peroxidation, and therefore indicators of 
injure [135]. The mechanism by which melatonin detoxifies 
highly reactive oxidants is donating an electron to these elec-
trophylic compounds [73]. Thereafter, the indolyl cation 
formed by the transfer of one electron in the presence of the 
O2
• becomes the metabolite kynuramine [88]. 
  The protective effects against lipid peroxidation by mela-
tonin has been evaluated extensively [61] utilizing xenobi-
otic substances such as paraquat and diquat, substances that 
in presence of p450 NADPH-cytochrome reductase induces 
the generation of O2
• [82, 132, 138]. Melatonin adminis-
tered to rats previously injected with paraquat or diquat pre-
vents oxidative changes in liver, lungs and kidneys and in-
creases survival of the animals. In addition, in animals 
treated with LPS, melatonin abolished the increment in lipid 
peroxidation and managed to offset the hepatic degenerative 
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tonin prevented carbon tetrachloride (CCl4) damage, CCl4 is 
a toxin metabolized by cytochrome p450, to produce 
trichlorometyl radicals and cause the production of other free 
radicals which produce lipid peroxidation in the kidney and 
liver. In other studies, rat brain homogenates were incubated 
with kainate or hydrogen peroxide resulting in lipid peroxi-
dation, but in the presence of melatonin, there was a reduc-
tion in lipid damage. Additionally, melatonin’s effect was in 
a dose-dependent fashion [61, 83]. There are a number of 
characteristics which melatonin possess which aids its ability 
to inhibit lipid peroxidation: a) it is highly lipid soluble 
[100]; b) It scavenges OH
• radicals, which toxic enough to 
initiate lipid peroxidation [92, 98]; c) it increases the efficacy 
of other antioxidants as vitamin E [15, 92, 97, 98] and vita-
min C[35]; d) it may scavenge peroxyl radicals (ROO
•) [94, 
99] who propagate peroxidation, as well as the highly reac-
tive singlet oxygen [35]; e) it increases the activity of glu-
thatione peroxidase and superoxide dismutase [35, 92, 95]. 
  In rat brain homogenates in the presence of NO, liberated 
by sodium nitroprusiate [116] it was possible to protect 
against the lipid membrane peroxidation with melatonin or 
vitamin E. The neuroprotective effects of melatonin have 
also been shown other conditions: a) the oxidative effects of 
hyperbaric oxygen exposure [84, 131]; b) after the induction 
of transitory cerebral ischemia and reperfusion in gerbils [44, 
86]; c) the combination of diverse effects on antioxidant en-
zymes, the direct elimination of free radicals, the clear access 
through all morphological barriers and the penetration to all 
subcellular compartments, are characteristics that make 
melatonin potentially important factor in the antioxidant de-
fense system [35, 48, 82, 92, 95, 97]; d) in grastrointestinal 
lesions in rats induced by ethanol, indomethacin or acetic 
acid [71, 80]; e) lesions in hippocampus and striatum in-
duced by MPTP; in this case melatonin is proposed as a fea-
sible alternative to the management of PD [1, 32]. 
  It is known that lipid peroxidation disturbs order and the 
lipid dynamic in biological membranes. After oxidative 
stress, membrane fluidity, a parameter that reflects activity in 
the phospholipid bilayer, is decreased [28]. Melatonin pre-
serves efficiently microsomal membranes against the rigidity 
induced by lipid peroxidation [37]. The importance of these 
findings resides in the close relation of numerous membrane 
functions with membrane fluidity, i.e. signal transduction, 
solute transport, and inactivity of membrane-associated en-
zymes [42, 115]. Even slight alterations in membrane fluid-
ity are related with aberrant cellular function and neurologi-
cal disease [135, 139, 140]. Recently, it was shown that pin-
ealectomy, which leads to a drop of melatonin concentrations 
in the blood, worsen the rigidity in the microsomal mem-
branes due to aging [101]. The ability of melatonin to pre-
vent membrane rigidity mediated by oxidative stress sug-
gests that melatonin may play some cell protective actions 
because of it stabilizes cellular membranes. 
MELATONIN AS A NEUROCYTOSKELETAL PRO-
TECTOR: IMPORTANCE FOR NEURONAL PLAS-
TICITY AND SYNAPTIC CONNECTIVITY LOST IN 
NEURODEGENERATION 
 H 2O2 causes loss of neurites and a cytoskeletal retraction 
toward the perinuclear region. Melatonin prevents micro-
filament and microtubule collapse in N1E-115 cells as well 
as the increased lipid peroxidation and apoptosis caused by 
H2O2. Our findings also indicate that melatonin restores neu-
rite formation, microtubule enlargement, and microfilament 
organization in microspikes and growth cones in cells cul-
tured with H2O2. While, the PKC agonist caused cytoskeletal 
reorganization in the presence of H2O2, the PKC inhibitor, 
bis-indolylmaleimide, blocked neurite formation and cy-
toskeletal reorganization elicited by melatonin. In addition, 
the CaM antagonist, ophiobolin, was not able to protect the 
cells against the damage caused by H2O2. However, PMA 
and ophiobolin resembled the melatonin effects in cells 
treated with H2O2 and a cytoskeleton organized in neurites 
and a network all over the cytoplasm was observed. By con-
trast, the melatonin receptor antagonist did not abolish the 
protective effects of melatonin against the damage caused by 
H2O2. Our data suggest that melatonin can be a potential 
therapeutic agent in the treatment of neurodegenerative dis-
eases through prevention of the cytoskeletal damage caused 
by free radicals and by restoration of cytoskeletal organiza-
tion and neurite formation. 
  Since melatonin levels often are decreased in psychiatric 
illnesses, and as we described here the indolamine elicits 
neurite formation, it is plausible that the low levels of mela-
tonin found in patients with schizophrenia and depression 
affect neurite formation and therefore neurodevelopment in 
these individuals. Furthermore, abnormalities in the process 
of neurite outgrowth could explain increased pruning found 
in patients with schizophrenia as abnormally formed neurites 
could be prone to higher rates of removal. Moreover, discon-
nectivity between brain structures, which has been proposed 
as the anatomical basis for psychosis could result from de-
fects in neurite formation associated with low levels of mela-
tonin. These data suggest that melatonin could have utility in 
the treatment of schizophrenia but this needs further study 
[11]. 
  Melatonin, the main product synthesized by the pineal 
gland has important properties that make this compound use-
ful in the treatment of dementia [85, 96, 102]. This indole is 
a potent free radical scavenger and also it governs the as-
sembly of the three main cytoskeletal components stimulat-
ing neuritogenesis [11]. In N1E-115 cells, melatonin in-
creases neurite formation and in this process participate the 
selective activation of the alpha isoform of PKC. Activation 
of PKC alpha is followed by its translocation from the cyto-
sol to the membrane cytoskeletal fraction and increased 
vimentin phosphorylation and vimentin intermediate fila-
ment reorganization [9]. Moreover, in MDCK epithelial 
cells, melatonin through PKC activation increases vinculin 
phosphorylation and focal adhesion formation, a process that 
implies cytoskeletal reorganization [90]. Additionally, mela-
tonin antagonism to Ca
2+/Calmodulin (CaM) decreases the 
activity and autophosphorylation of CaM kinase II, a key 
protein kinase, involved in neurite maturation [12], and 
caused neurite enlargement through an increase in tubulin 
polymerization caused by its CaM antagonism [55]. Re-
cently, we showed in N1E-115 cells that melatonin preclude 
microfilament and microtubule collapse as well as the in-
creased lipid peroxidation and apoptosis caused by free radi-
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the indole restores neurite formation, microtubule enlarge-
ment, and microfilament organization in microspikes and 
growth cones in cells damaged with H2O2 through PKC acti-
vation. The PKC agonist, phorbol 12-myristate 13-acetate 
(PMA) caused cytoskeletal reorganization in the presence of 
H2O2, while the PKC inhibitor, bisindolylmaleimide, blocked 
neurite formation and microfilament reorganization elicited 
by melatonin. Thus, the stimulatory properties of melatonin 
on neuritogenesis as well as its modulatory actions on cy-
toskeletal protein phosphorylation suggest that melatonin 
may reestablish neurite formation and the basal levels of 
phosphorylated tau in N1E-115 cells treated with okadaic 
acid. Thus, in the present study, we evaluated the effects of 
melatonin in neuritogenesis by counting the damage rounded 
cells as well as cells bearing microspikes and neurites. Also, 
we measured the amount of phosphorylated levels of tau in 
N1E-115 cells treated with okadaic acid and melatonin. The 
results showed that in N1E-115 cells, melatonin reestab-
lished neuritogenesis in okadaic damaged cells and blocked 
abnormal tau phosphorylation caused by this compound. 
Data strongly suggest that melatonin may improve cognition 
by impeding neuronal damage caused by tau hyperphos-
phorylation and cytoskeletal collapse and through establish-
ing new neuronal pathways by neuritogenesis stimulation. 
  To test whether melatonin at the physiological cerebro-
spinal fluid circulating concentration modified hyperphos-
phorylation of tau caused by okadaic acid, protein cell ho-
mogenates were separated in SDS-PAGE, proteins trans-
ferred to nitrocellulose paper and tau identified by Western 
blot by using an antibody that recognized phosphorylated 
404 serine and C-17 antibody that recognized two tau iso-
forms at carboxyl terminal site. Fig. (2) show that okadaic 
acid treatment increased the phosphorylation of tau at Ser-
404. Melatonin added before, simultaneously or after oka-
daic acid treatment decreased tau hyperphosphorylation 
caused by this compound respectively (Fig. 2, A-B). Densi-
tometric analysis showed that okadaic acid augmented phos-
phorylated tau by 121% regarding the vehicle incubated 
cells. While melatonin decreased the relative quantity of 
phospho-tau when was added before, simultaneously, or after 
okadaic acid by 76%, 41%, 81%, respectively (Fig. 2). No 
differences were found when tau was recognized by C-17 
Fig. (2). Melatonin effects on cytoskeletal alterations produced by okadaic acid (OA) or hydrogen peroxide (H2O2) in N1E-115 cells. (A)
N1E-115 cells were incubated with the vehicle (VEH), 15 nM OA for 24 h (OA), 100 M H2O2 for 1 h (H2O2), 0.1 M melatonin for 6 h 
before treatment with 15 nM okadaic acid for 24 h (MEL+AO) or 0.1 M melatonin for 3 h before 1 h treatment with 100 M H2O2 (MEL+ 
H2O2) Cultures were fixed and simultaneously stained with an antitubulin antibody (green), RITC-phalloidin (red) and DAPI for detection of 
microtubules, actin microfilaments and the nucleus, respectively. Bar = 10 mm. (B) Melatonin effects on tau hyperphosphorylation induced 
by OA in N1E-115 cells. 1) Melatonin effects in phospho-tau levels were analyzed by Western blot. Cells were incubated with the VEH, OA 
and MEL+OA. Representative autoradiogram of p-tau in the VEH, OA, or MEL+OA. 2) Optical density (mm
2) of p-tau immunoreactivity is 
showed in the histogram. Results represent the mean ± S.E.M. of three experiments done in quadruplicate. (C) Melatonin effect on lipid per-
oxidation induced by OA and H2O2. Neuroblastoma cells were incubated with the VEH, H2O2, MEL+ H2O2, OA and MEL+OA. Cells were 
homogenized and both MDA and 4-HDA were quantified. Results represent the mean ± SEM of three experiments done in duplicate. Cellular and Biochemical Actions of Melatonin  Current Neuropharmacology, 2008, Vol. 6, No. 3    211
antibody in cell extracts obtained from cells cultured with 
okadaic acid, melatonin or combination of melatonin and 
okadaic acid treatments. 
  Neuroprotective actions of melatonin have been shown to 
occur through its intracellular antioxidant mechanisms and 
its neurocytoskeletal protective effects. Previously, we 
showed in N1E-115 cells damaged with H2O2 that melatonin 
restored neurite formation, microtubule enlargement, and 
microfilament organization in microspikes and growth cones. 
Hyperphosphorylation of tau has been shown to occur asso-
ciated with high levels of oxidative stress and considered as 
an important hallmark of most neurodegenerative diseases. 
Moreover, we observed in N1E-115 cells that melatonin pre-
vented microtubule disruption as well as increased lipid per-
oxidation and apoptosis caused by the phosphatase inhibitor 
okadaic acid (OA), a specific inhibitor of the serine/ 
threonine proteins phosphatases 1 and 2A that induces mo-
lecular and structural changes similar to those found in Alz-
heimer’s disease. It is known that tau protein plays a key role 
in microtubule stabilization and in neurite formation and that 
dynamic change in microfilament organization also occurs 
during neurite formation. Therefore, in this work we evalu-
ated the effects of melatonin on neuritogenesis and tau phos-
phorylation in N1E-115 cells incubated for 24 h with 15 nM 
OA in the presence of 10
-11, 10
-7 or 10
-5 M melatonin added 
before, simultaneously or after OA treatment. 
  Microfilament organization was studied by RITC-
phalloidin staining and fluorescence microscopy. Tau phos-
phorylation and tau levels were determined by Western Blot. 
The proteins were immunodetected by using a specific anti-
body that recognizes the tau´s 404 serine and the C-17 anti-
body that recognizes the tau COOH terminal sequence. The 
results showed that OA causes microfilament retraction to-
ward the perinuclear region. The effect of OA was partially 
prevented by melatonin added 6h before simultaneously or 
after OA treatment. In addition, we found that melatonin 
added before, simultaneously or after OA treatment abol-
ished tau hyperphosphorylation caused by OA. The results 
strongly suggest that melatonin acts as a neurocytoskeletal 
protector by decreasing tau hyperphoshorylation preserving 
the cytoskeletal structure. Data strongly suggest that mela-
tonin may improve cognition by impeding neuronal damage 
by hyperphosphorylation and through establishing new neu-
ronal pathways.  
CONCLUDING REMARKS 
  Oxidative stress is a critical aspect of age-associated dis-
eases, such as cancer, heart diseases and neurodegeneration. 
Most of free radical-related pathologies may have some an-
other origin, but the common pathway once the process has 
begun, is oxidative damage. Since oxidative damage has the 
inherent capacity for perpetuating itself, free radical damage 
can be very severe. 
  Oxidant damage and mitochondrial dysfunction go to-
gether. This occurs under “normal” conditions in ageing, and 
under a variety of pathological conditions. Antioxidants, 
including melatonin should be tested for their efficacy in 
reducing the degenerative sign of aging as well as a protec-
tive agent against age-associated diseases that have an oxida-
tive stress component.  
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